{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:22:28Z","timestamp":1790738548814,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Higher Education Innovation Fund project of Gansu Province","award":["no. 2025B-23"],"award-info":[{"award-number":["no. 2025B-23"]}]},{"name":"Cuiying Scientific and Technological Innovation Program of The Second Hospital & Clinical Medical School, Lanzhou University","award":["no. CY2023-MS-B18"],"award-info":[{"award-number":["no. CY2023-MS-B18"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06643-0","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:57:57Z","timestamp":1761623877000},"page":"4931-4948","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Qinyi","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxiang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"6643_CR1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O\u2019Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, D\u00f6hner K, Schlenk RF, D\u00f6hner H, Campbell PJ (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209\u20132221. https:\/\/doi.org\/10.1056\/NEJMoa1516192","journal-title":"N Engl J Med"},{"key":"6643_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, L\u00f6wenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"6643_CR3","doi-asserted-by":"publisher","first-page":"100829","DOI":"10.1016\/j.blre.2021.100829","volume":"49","author":"M de Lima","year":"2021","unstructured":"de Lima M, Roboz GJ, Platzbecker U, Craddock C, Ossenkoppele G (2021) AML and the Art of remission maintenance. Blood Rev 49:100829. https:\/\/doi.org\/10.1016\/j.blre.2021.100829","journal-title":"Blood Rev"},{"key":"6643_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","volume":"31","author":"M Heuser","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A, Buske C (2020) Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:697\u2013712. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.018","journal-title":"Ann Oncol"},{"key":"6643_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","volume":"126","author":"F Thol","year":"2015","unstructured":"Thol F, Schlenk RF, Heuser M, Ganser A (2015) How I treat refractory and early relapsed acute myeloid leukemia. Blood 126:319\u2013327. https:\/\/doi.org\/10.1182\/blood-2014-10-551911","journal-title":"Blood"},{"key":"6643_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136\u20131152. https:\/\/doi.org\/10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"key":"6643_CR7","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.25162","volume":"93","author":"C Ganzel","year":"2018","unstructured":"Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O\u2019Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS (2018) Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol 93:1074\u20131081. https:\/\/doi.org\/10.1002\/ajh.25162","journal-title":"Am J Hematol"},{"key":"6643_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hon.2995","volume":"40","author":"E Shumilov","year":"2022","unstructured":"Shumilov E, Hasenkamp J, Maulhardt M, Mazzeo P, Schmidt N, Boyadzhiev H, Jung W, Ganster C, Haase D, Koch R, Wulf G (2022) Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed\/refractory acute myeloid leukemia: A unicentric retrospective analysis. Hematol Oncol 40:763\u2013776. https:\/\/doi.org\/10.1002\/hon.2995","journal-title":"Hematol Oncol"},{"key":"6643_CR9","doi-asserted-by":"publisher","unstructured":"Salah HT, DiNardo CD, Konopleva M, Khoury JD (2021) Potential biomarkers for treatment response to the BCL-2 inhibitor venetoclax: state of the Art and future directions. Cancers 13. https:\/\/doi.org\/10.3390\/cancers13122974","DOI":"10.3390\/cancers13122974"},{"key":"6643_CR10","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s41419-024-07140-4","volume":"15","author":"M Tambe","year":"2024","unstructured":"Tambe M, Unterberger S, Kriegbaum MC, V\u00e4nttinen I, Olgac EJ, V\u00e4h\u00e4-Koskela M, Kontro M, Wennerberg K, Heckman CA (2024) Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP Inhibition and Azacitidine. Cell Death Dis 15:750. https:\/\/doi.org\/10.1038\/s41419-024-07140-4","journal-title":"Cell Death Dis"},{"key":"6643_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M (2017) Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma 58:1\u201317. https:\/\/doi.org\/10.1080\/10428194.2017.1283032","journal-title":"Leuk Lymphoma"},{"key":"6643_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","volume":"636","author":"J Sango","year":"2024","unstructured":"Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, Tomalin LE, Cruz-Rodriguez N, Wang T, Olszewska M, Olivier E, Jaud M, Nadorp B, Kroger B, Hu F, Silverman L, Chung SS, Wagenblast E, Chaligne R, Eisfeld AK, Demircioglu D, Landau DA, Lito P, Papaemmanuil E, DiNardo CD, Hasson D, Konopleva M, Papapetrou EP (2024) RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature 636:241\u2013250. https:\/\/doi.org\/10.1038\/s41586-024-08137-x","journal-title":"Nature"},{"key":"6643_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM, Glytsou C, Fleming SA, Zhang Q, Ma H, Patel KP, Kornblau SM, Xu Z, Chua CC, Chen X, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang DCS, Roberts AW, Majewski IJ, Konopleva M, Wei AH (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988","journal-title":"Blood"},{"key":"6643_CR14","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood.2022016090","volume":"141","author":"DM Moujalled","year":"2023","unstructured":"Moujalled DM, Brown FC, Chua CC, Dengler MA, Pomilio G, Anstee NS, Litalien V, Thompson E, Morley T, MacRaild S, Tiong IS, Morris R, Dun K, Zordan A, Shah J, Banquet S, Halilovic E, Morris E, Herold MJ, Lessene G, Adams JM, Huang DCS, Roberts AW, Blombery P, Wei AH (2023) Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia. Blood 141:634\u2013644. https:\/\/doi.org\/10.1182\/blood.2022016090","journal-title":"Blood"},{"key":"6643_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.106346","author":"S Shabestari","year":"2024","unstructured":"Shabestari S, Pourmadadi M, Abdouss H, Ghanbari T, bazari S, Abdouss M, Rahdar A, Romanholo Ferreira L (2024) Unlocking the potential of cytarabine: A comprehensive review from molecular insights to advanced nanoformulations and Co-delivery strategies for enhanced drug efficacy. J Drug Delivery Sci Technol J Drug Delivery Sci Technol. https:\/\/doi.org\/10.1016\/j.jddst.2024.106346","journal-title":"J Drug Delivery Sci Technol J Drug Delivery Sci Technol"},{"key":"6643_CR16","doi-asserted-by":"publisher","first-page":"692497","DOI":"10.3389\/fonc.2021.692497","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Ye J, Yang Y, Zhao Y, Shen H, Ye X, Xie W (2021) The basic research of the combinatorial therapy of ABT-199 and Homoharringtonine on acute myeloid leukemia. Front Oncol 11:692497. https:\/\/doi.org\/10.3389\/fonc.2021.692497","journal-title":"Front Oncol"},{"key":"6643_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/joim.13738","volume":"295","author":"S Yu","year":"2024","unstructured":"Yu S, Zhang Y, Yu G, Wang Y, Shao R, Du X, Xu N, Lin D, Zhao W, Zhang X, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Liu Q, Lin R, Jiang X, Xuan L, Liu Q, Jin H (2024) Sorafenib plus triplet therapy with venetoclax, Azacitidine and Homoharringtonine for refractory\/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study. J Intern Med 295:216\u2013228. https:\/\/doi.org\/10.1111\/joim.13738","journal-title":"J Intern Med"},{"key":"6643_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s00432-024-05861-9","volume":"150","author":"Z Yin","year":"2024","unstructured":"Yin Z, Yao Z, Chen D, Zhang Y, Weng G, Du X, Lin D, Xiao J, Sun Z, Zhang H, Liang X, Guo Z, Zhao W, Xuan L, Jiang X, Shi P, Liu Q, Ping B, Yu G (2024) Homoharringtonine May help improve the outcomes of venetoclax and Azacitidine in AML1-ETO positive acute myeloid leukemia. J Cancer Res Clin Oncol 150:336. https:\/\/doi.org\/10.1007\/s00432-024-05861-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"6643_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed) 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ (Clinical Res ed)"},{"key":"6643_CR20","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/jco.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, L\u00f6wenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the international working group for Diagnosis, standardization of response Criteria, treatment Outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncology: Official J Am Soc Clin Oncol 21:4642\u20134649. https:\/\/doi.org\/10.1200\/jco.2003.04.036","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"6643_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood 108:419\u2013425. https:\/\/doi.org\/10.1182\/blood-2005-10-4149","journal-title":"Blood"},{"key":"6643_CR22","unstructured":"U.S. Department of Health and Human Services NIoH, National Cancer Institute (2010) Common terminology criteria for adverse events (CTCAE), version 4.03. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute."},{"key":"6643_CR23","unstructured":"Wells GS, O\u2019Connell D, Peterson J, Welch VA, Losos M, Tugwel P (2022) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses"},{"key":"6643_CR24","doi-asserted-by":"publisher","unstructured":"Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, Rey J, D\u2019Incan E, Charbonnier A, Villetard F, Maisano V, Lombardi L, Ittel A, Mozziconacci MJ, Gelsi-Boyer V, Vey N (2022) Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers 14 https:\/\/doi.org\/10.3390\/cancers14082025","DOI":"10.3390\/cancers14082025"},{"key":"6643_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/ejh.14140","volume":"112","author":"C Petit","year":"2024","unstructured":"Petit C, Saillard C, Mohty B, Hicheri Y, Villetard F, Maisano V, Charbonnier A, Rey J, D\u2019Incan E, Rouzaud C, Gelsi-Boyer V, Murati A, Lhoumeau AC, Ittel A, Mozziconacci MJ, Alary AS, Hospital MA, Vey N, Garciaz S (2024) Azacitidine-venetoclax versus Azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients. Eur J Haematol 112:530\u2013537. https:\/\/doi.org\/10.1111\/ejh.14140","journal-title":"Eur J Haematol"},{"key":"6643_CR26","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/jco.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F (2024) Azacitidine, Venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-Mutated AML. J Clin Oncology: Official J Am Soc Clin Oncol 42:1499\u20131508. https:\/\/doi.org\/10.1200\/jco.23.01911","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"6643_CR27","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD (2021) Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv 5:1552\u20131564. https:\/\/doi.org\/10.1182\/bloodadvances.2020003734","journal-title":"Blood Adv"},{"key":"6643_CR28","doi-asserted-by":"publisher","first-page":"1370405","DOI":"10.3389\/fonc.2024.1370405","volume":"14","author":"F Angotzi","year":"2024","unstructured":"Angotzi F, Lessi F, Leoncin M, Fil\u00ec C, Endri M, Lico A, Visentin A, Pravato S, Candoni A, Trentin L, Gurrieri C (2024) Efficacy and safety of venetoclax plus hypomethylating agents in relapsed\/refractory acute myeloid leukemia: a multicenter real-life experience. Front Oncol 14:1370405. https:\/\/doi.org\/10.3389\/fonc.2024.1370405","journal-title":"Front Oncol"},{"key":"6643_CR29","doi-asserted-by":"crossref","unstructured":"Aktimur S, Gunes A, Akidan O, Karatas A, Turgut M (2020) Efficacy of the combination of venetoclax and Azacitidine in elderly of frail relapsed\/ refractory patients with acute myeloid leukemia, first multi-institutional real world experience from Turkey. UHOD - Uluslararasi Hematoloji-Onkoloji dergisi. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi","DOI":"10.4999\/uhod.204358"},{"key":"6643_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1078-0432.Ccr-24-1332","volume":"31","author":"G Yu","year":"2025","unstructured":"Yu G, Zhang Y, Yu S, Yin Z, Weng G, Xu N, Du X, Lin D, Xiao J, Sun Z, Zhang H, Liang X, Guo Z, Zhao W, Dai M, Fan Z, Xuan L, Liu H, Xu D, Ye J, Jiang X, Shi P, Jin H, Liu Q (2025) Homoharringtonine added to venetoclax and Azacitidine improves outcome and mitigates genetic impact in Relapsed\/Refractory AML: A multicenter cohort study. Clin Cancer Research: Official J Am Association Cancer Res 31:87\u201397. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1332","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"6643_CR31","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1080\/10428194.2022.2062345","volume":"63","author":"NJ Short","year":"2022","unstructured":"Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N (2022) A multi-arm phase Ib\/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed\/refractory acute myeloid leukemia. Leuk Lymphoma 63:2161\u20132170. https:\/\/doi.org\/10.1080\/10428194.2022.2062345","journal-title":"Leuk Lymphoma"},{"key":"6643_CR32","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.3324\/haematol.2024.285014","volume":"109","author":"GSG Murthy","year":"2024","unstructured":"Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, Atallah E (2024) A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed\/refractory acute myeloid leukemia. Haematologica 109:2864\u20132872. https:\/\/doi.org\/10.3324\/haematol.2024.285014","journal-title":"Haematologica"},{"key":"6643_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000525566","volume":"145","author":"SP Desikan","year":"2022","unstructured":"Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ (2022) A phase II study of Azacitidine, Venetoclax, and Trametinib in relapsed or refractory acute myeloid leukemia harboring RAS Pathway-Activating mutations. Acta Haematol 145:529\u2013536. https:\/\/doi.org\/10.1159\/000525566","journal-title":"Acta Haematol"},{"key":"6643_CR34","doi-asserted-by":"publisher","first-page":"107564","DOI":"10.1016\/j.leukres.2024.107564","volume":"145","author":"Q Fu","year":"2024","unstructured":"Fu Q, Wang Y, Liu H, Gao H, Sun W, Jiang Q, Jiang H, Liu K, Huang X, Tang F (2024) Triplet therapy with gilteritinib, venetoclax, and Azacitidine for relapsed\/refractory FLT3(mut) acute myeloid leukemia. Leuk Res 145:107564. https:\/\/doi.org\/10.1016\/j.leukres.2024.107564","journal-title":"Leuk Res"},{"key":"6643_CR35","doi-asserted-by":"publisher","unstructured":"Labrador J, Saiz-Rodr\u00edguez M, de Miguel D, de Laiglesia A, Rodr\u00edguez-Medina C, Vidriales MB, P\u00e9rez-Encinas M, S\u00e1nchez-S\u00e1nchez MJ, Cuello R, Rold\u00e1n-P\u00e9rez A, Vives S, Benzo-Callejo G, Colorado M, Garc\u00eda-Fortes M, Sayas MJ, Olivier C, Recio I, Conde-Royo D, Bienert-Garc\u00eda \u00c1, Vahi M, Mu\u00f1oz-Garc\u00eda C, Seri-Merino C, Tormo M, Vall-Llovera F, Foncillas M, Mart\u00ednez-Cuadr\u00f3n D, Sanz M, Montesinos P (2022) Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Cancers 14. https:\/\/doi.org\/10.3390\/cancers14071734","DOI":"10.3390\/cancers14071734"},{"key":"6643_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","volume":"16","author":"H Jin","year":"2023","unstructured":"Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, Lin D, Chen Y, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Yin Z, Xuan L, Lin R, Jiang X, Yu G, Liu Q (2023) Venetoclax combined with Azacitidine and Homoharringtonine in Relapsed\/Refractory AML: A Multicenter, phase 2 trial. J Hematol Oncol 16:42. https:\/\/doi.org\/10.1186\/s13045-023-01437-1","journal-title":"J Hematol Oncol"},{"key":"6643_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00277-021-04674-x","volume":"101","author":"P Zhao","year":"2022","unstructured":"Zhao P, Ni M, Ma D, Fang Q, Zhang Y, Li Y, Huang Y, Chen Y, Chai X, Zhan Y, Li Y, Kang Q, Zhao M, Liu M, Zhang F, Huang S, Wen S, Deng B, Wang J (2022) Venetoclax plus Azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. Ann Hematol 101:119\u2013130. https:\/\/doi.org\/10.1007\/s00277-021-04674-x","journal-title":"Ann Hematol"},{"key":"6643_CR38","doi-asserted-by":"publisher","unstructured":"You L, Liu Y, Mai W, Xie W, Zhou D, Mao L, Chen L, Zhou X, Ma L, Zheng X, Wei J, Lou Y, Ye X, Tong H, Jin J, Meng H (2024) Venetoclax plus cytarabine and Azacitidine in relapsed\/refractory AML: an open-label, single-arm, phase 2 study. Eur J Cancer (Oxford England: 1990) 202(113979). https:\/\/doi.org\/10.1016\/j.ejca.2024.113979","DOI":"10.1016\/j.ejca.2024.113979"},{"key":"6643_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12032-024-02302-y","volume":"41","author":"IM Bouligny","year":"2024","unstructured":"Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Ho T, Zacholski K, Venn C, Wages NA, Grant S, Maher KR (2024) Venetoclax with decitabine or Azacitidine in relapsed or refractory acute myeloid leukemia. Med Oncol (Northwood Lond Engl) 41:80. https:\/\/doi.org\/10.1007\/s12032-024-02302-y","journal-title":"Med Oncol (Northwood Lond Engl)"},{"key":"6643_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/16078454.2021.2024940","volume":"27","author":"A G\u00f3mez-De Le\u00f3n","year":"2022","unstructured":"G\u00f3mez-De Le\u00f3n A, Demichelis-G\u00f3mez R, Pinedo-Rodr\u00edguez A, Enriquez-Vera D, Flores-Jim\u00e9nez JA, Ceballos-L\u00f3pez AA, Rodr\u00edguez-Mejorada M, Herrera Riojas MA, Ovilla-Mart\u00ednez R, B\u00e1ez-Islas P, Cota-Rangel X, Neme-Yunes Y, Incl\u00e1n-Alarc\u00f3n S, L\u00f3pez-Flores NJ, Colunga-Pedraza PR, Rodr\u00edguez-Z\u00fa\u00f1iga AC, G\u00f3mez-Almaguer D (2022) Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America. Hematol (Amsterdam Netherlands) 27:249\u2013257. https:\/\/doi.org\/10.1080\/16078454.2021.2024940","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"6643_CR41","doi-asserted-by":"publisher","first-page":"2265206","DOI":"10.1080\/16078454.2023.2265206","volume":"28","author":"X Xu","year":"2023","unstructured":"Xu X, Liu R, He A, Wang F (2023) Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed\/refractory acute myeloid leukemia. Hematol (Amsterdam Netherlands) 28:2265206. https:\/\/doi.org\/10.1080\/16078454.2023.2265206","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"6643_CR42","doi-asserted-by":"publisher","first-page":"2198098","DOI":"10.1080\/16078454.2023.2198098","volume":"28","author":"Y Du","year":"2023","unstructured":"Du Y, Li C, Yan J (2023) The efficacy and safety of venetoclax and Azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. Hematol (Amsterdam Netherlands) 28:2198098. https:\/\/doi.org\/10.1080\/16078454.2023.2198098","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"6643_CR43","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1186\/s12885-024-13000-3","volume":"24","author":"N Jiao","year":"2024","unstructured":"Jiao N, Shi L, Wang S, Sun Y, Bai Y, Zhang D (2024) Efficacy and safety of venetoclax combination therapy for relapsed\/refractory acute myeloid leukemia: a systematic review and meta-analysis. BMC Cancer 24:1271. https:\/\/doi.org\/10.1186\/s12885-024-13000-3","journal-title":"BMC Cancer"},{"key":"6643_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/s1470-2045(18)30010-x","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA (2018) Safety and preliminary efficacy of venetoclax with decitabine or Azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19:216\u2013228. https:\/\/doi.org\/10.1016\/s1470-2045(18)30010-x","journal-title":"Lancet Oncol"},{"key":"6643_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3324\/haematol.2023.282912","volume":"109","author":"R Shahswar","year":"2024","unstructured":"Shahswar R, Beutel G, Gabdoulline R, Schwarzer A, Kloos A, Koenecke C, Stadler M, Gohring G, Behrens YL, Li Z, Dallmann LK, Klement P, Albert C, Wichmann M, Alwie Y, Benner A, Saadati M, Ganser A, Thol F, Heuser M (2024) Fludarabine, cytarabine, and Idarubicin with or without venetoclax in patients with relapsed\/refractory acute myeloid leukemia. Haematologica 109:72\u201383. https:\/\/doi.org\/10.3324\/haematol.2023.282912","journal-title":"Haematologica"},{"key":"6643_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ejh.14302","volume":"114","author":"K Wille","year":"2025","unstructured":"Wille K, Dumke M, Wilsdorf N, Sadjadian P, Schneider A, Jender-Bartling S, Kolatzki V, Horstmann A, Meixner R, Jim\u00e9nez-Mu\u00f1oz M, Fuchs C, Tischler HJ, Griesshammer M (2025) Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia. Eur J Haematol 114:17\u201325. https:\/\/doi.org\/10.1111\/ejh.14302","journal-title":"Eur J Haematol"},{"key":"6643_CR47","doi-asserted-by":"publisher","first-page":"e1663","DOI":"10.1634\/theoncologist.2020-0818","volume":"25","author":"H Wang","year":"2020","unstructured":"Wang H, Wang L, Li C, Wuxiao Z, Shao R, Wang H, Lu Y (2020) Cladribine with granulocyte Colony-Stimulating Factor, Cytarabine, and aclarubicin regimen in Refractory\/Relapsed acute myeloid leukemia: A phase II multicenter study. Oncologist 25:e1663\u2013e1670. https:\/\/doi.org\/10.1634\/theoncologist.2020-0818","journal-title":"Oncologist"},{"key":"6643_CR48","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood.2021013156","volume":"139","author":"CP Mill","year":"2022","unstructured":"Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN (2022) Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood 139:907\u2013921. https:\/\/doi.org\/10.1182\/blood.2021013156","journal-title":"Blood"},{"key":"6643_CR49","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1182\/bloodadvances.2022008625","volume":"7","author":"AN Saliba","year":"2023","unstructured":"Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM (2023) Pevonedistat with Azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv 7:2360\u20132363. https:\/\/doi.org\/10.1182\/bloodadvances.2022008625","journal-title":"Blood Adv"},{"key":"6643_CR50","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.Cd-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, Lasater EA, Shi Y, Dave N, Riehm JJ, Robinson VA, Do AD, Li Y, Orr CJ, Sampath D, Raval A, Merchant M, Bhathena A, Salem AH, Hamel KM, Leverson JD, Donawho C, Pappano WN, Uziel T (2021) Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint Blockade. Cancer Discov 11:68\u201379. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-0759","journal-title":"Cancer Discov"},{"key":"6643_CR51","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med 381:1728\u20131740. https:\/\/doi.org\/10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"key":"6643_CR52","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3324\/haematol.2018.205534","volume":"105","author":"L Han","year":"2020","unstructured":"Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M (2020) Concomitant targeting of BCL2 with venetoclax and MAPK signaling with Cobimetinib in acute myeloid leukemia models. Haematologica 105:697\u2013707. https:\/\/doi.org\/10.3324\/haematol.2018.205534","journal-title":"Haematologica"},{"key":"6643_CR53","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1182\/bloodadvances.2021005585","volume":"6","author":"A Bataller","year":"2022","unstructured":"Bataller A, Garrido A, Guijarro F, O\u00f1ate G, Diaz-Bey\u00e1 M, Arnan M, Tormo M, Vives S, de Llano MPQ, Coll R, Gallardo D, Vall-Llovera F, Escoda L, Garcia-Gui\u00f1on A, Salamero O, Sampol A, Merchan BM, Bargay J, Casta\u00f1o-D\u00edez S, Esteban D, Oliver-Cald\u00e9s A, Rivero A, Mozas P, L\u00f3pez-Guerra M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomded\u00e9u JF, Colomer D, Brunet S, Sierra J, Esteve J (2022) European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv 6:1193\u20131206. https:\/\/doi.org\/10.1182\/bloodadvances.2021005585","journal-title":"Blood Adv"},{"key":"6643_CR54","doi-asserted-by":"publisher","first-page":"21615","DOI":"10.1002\/cam4.6696","volume":"12","author":"E Chen","year":"2023","unstructured":"Chen E, Jiao C, Yu J, Gong Y, Jin D, Ma X, Cui J, Wu Z, Zhou J, Wang H, Su B, Ge J (2023) Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China. Cancer Med 12:21615\u201321626. https:\/\/doi.org\/10.1002\/cam4.6696","journal-title":"Cancer Med"},{"key":"6643_CR55","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","volume":"97","author":"JE Meg\u00edas-Vericat","year":"2018","unstructured":"Meg\u00edas-Vericat JE, Mart\u00ednez-Cuadr\u00f3n D, Sanz M, Montesinos P (2018) Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review. Ann Hematol 97:1115\u20131153. https:\/\/doi.org\/10.1007\/s00277-018-3304-y","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06643-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06643-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06643-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T20:02:42Z","timestamp":1763236962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06643-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6643"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06643-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}